Cytokinetics
Trade Cytokinetics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CYTK
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
CYTK Key Statistics
Stock Snapshot
As of today, Cytokinetics(CYTK) shares are valued at $60.87. The company's market cap stands at 7.68B, with a P/E ratio of -9.55.
On 2026-03-09, Cytokinetics(CYTK) stock moved within a range of $59.91 to $63.14. With shares now at $60.87, the stock is trading +1.6% above its intraday low and -3.6% below the session's peak.
Trading volume for Cytokinetics(CYTK) stock has reached 2.56M, versus its average volume of 2.23M.
The stock's 52-week range extends from a low of $29.31 to a high of $70.98.
The stock's 52-week range extends from a low of $29.31 to a high of $70.98.
CYTK News
Recent analyst updates following Cytokinetics (CYTK) fourth quarter results and the launch of its heart drug Myqorzo have put fresh attention on the stock as in...
Key Points 15,000 shares were sold for a transaction value of approximately $928,950 at a weighted average price of around $61.93 per share on Feb. 5, 2026. T...
In late February 2026, Cytokinetics filed a US$47.17 million shelf registration for 750,000 common shares tied to an ESOP-related offering and reported fourth-q...
Analyst ratings
86%
of 21 ratingsMore CYTK News
New insider activity at Cytokinetics ( (CYTK) ) has taken place on March 5, 2026. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful inves...
Cytokinetics ((CYTK)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund-level data an...